Bispecific Antibodies Patent Landscape 2026
Bispecific Antibodies Patent Landscape in 2026
The bispecific antibodies patent field spans 13,688 patent families and is dominated by a tight cluster of large-cap biopharma, with Genentech holding the leading position and the top five filers collectively accounting for nearly a third of activity among the hundred largest filers. The field reached peak annual volume in 2021 and has since eased, signaling a maturing competitive environment where differentiation increasingly depends on engineering approach and therapeutic indication rather than sheer filing volume.
Genentech leads a concentrated field with a visible tier gap below the top three
Genentech holds the top-ranked position with 18,677 patent records, followed by Regeneron Pharmaceuticals at 9,925 and F. Hoffmann-La Roche at 7,796. These three incumbents together form a distinct leading tier that is well ahead of the remaining ranked applicants.
The top five filers — Genentech, Regeneron, Roche, Amgen, and Chugai Pharma — collectively represent 32% of the hundred largest filers’ combined activity, indicating meaningful but not extreme concentration. A second tier anchored by Janssen Biotech, Novartis, AbbVie, Pfizer, and MedImmune holds positions four through ten, while a long tail of academic medical centers and specialized biotechs occupies the remaining ranks.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Genentech Inc | 18,677 | |
| 2 | Regeneron Pharmaceuticals Inc | 9,925 | |
| 3 | F HOFFMANN LA ROCHE & CO AG | 7,796 | |
| 4 | Amgen Inc | 6,077 | |
| 5 | Chugai Pharmaceutical Co Ltd | 4,262 | |
| 6 | Janssen Biotech Inc | 4,022 | |
| 7 | Novartis AG | 3,914 | |
| 8 | AbbVie Inc | 2,924 | |
| 9 | Pfizer Inc | 2,645 | |
| 10 | MedImmune Ltd | 2,550 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Regents of the University of California | 2,456 | |
| 12 | Bristol Myers Squibb Co | 2,431 | |
| 13 | Amgen Research (Munich) GmbH | 2,235 | |
| 14 | Memorial Sloan Kettering Cancer Center | 2,053 | |
| 15 | Board of Regents, The University of Texas System | 2,007 | |
| 16 | The Government of the United States of America | 2,004 | |
| 17 | MacroGenics Inc | 1,953 | |
| 18 | Seagen Inc | 1,942 | |
| 19 | Dana-Farber Cancer Institute Inc | 1,867 | |
| 20 | The Trustees of the University of Pennsylvania | 1,740 |
Genentech’s position — roughly double the nearest challenger’s record count — suggests substantial depth in both structural engineering and therapeutic-application claims. The close alignment of Roche and Genentech at the top reflects the Roche group’s coordinated filing strategy across multiple legal entities.
The most recent 18–24 months of filing data are subject to publication lag and will likely be revised upward as pending applications publish; current late-period figures should be treated as incomplete. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Activity peaked in 2021; structural proteins dominate but adjacent branches remain sparse
Two charts together reveal a field that expanded rapidly through 2021 and has since plateaued, while its technology composition remains heavily anchored in peptide/protein chemistry and medicinal preparation with several adjacent IPC branches showing notably lower coverage.
Annual filing trend
Annual filings climbed from 1,099 in 2017 to a peak of 2,194 in 2021, then eased to 1,905 in 2022 and 1,793 in 2023. Figures for 2024 and 2025 are substantially under-counted due to publication lag and should not be read as a continuing decline.
↗ Hover for values · click a bar to ask EurekaTechnology composition
C07K (Peptides & proteins) and A61K (Medicinal preparations) together account for the largest share of IPC-tagged records, reflecting the field’s core focus on antibody engineering and formulation. C12N (Microorganisms & genetic engineering) and G01N (Material analysis & testing) are present but at markedly lower levels, pointing to relative sparsity in production-biology and analytical-methods coverage.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents.
What the competitive structure means for R&D investment decisions
The combination of a maturing filing curve, a concentrated leader set, sparse collaboration data, and US-dominant jurisdiction coverage shapes the strategic options available to both incumbents and new entrants.
Field has plateaued near its 2021 peak
The lifecycle assessment places bispecific antibodies at a maturity stage, with annual filings having plateaued near their 2021 peak of 2,194. The multi-year window still reflects substantial accumulated activity, but incremental volume growth is no longer the primary dynamic. New entrants face a dense prior-art landscape; incumbents derive value from portfolio depth rather than first-mover novelty.
Lifecycle: MaturityTop three hold a durable lead; second tier is competitive
Genentech, Regeneron, and Roche form a clearly differentiated leading tier. The gap between rank three (7,796 records) and rank four (6,077, Amgen) is narrower, making the second tier more contestable. Specialized biotechs such as MacroGenics, Seagen, and Xencor occupy mid-table positions and may represent acquisition or partnership targets for larger players seeking platform differentiation.
High concentrationNo co-applicant data available in this corpus
The evidence base does not contain co-applicant or joint-filing records for this topic. The presence of academic institutions — including the Regents of the University of California, Memorial Sloan Kettering, and the University of Texas System — in the top-20 ranking suggests university-industry collaboration is structurally present, but the nature and extent of formal co-filing arrangements requires supplementary analysis.
Evidence pendingUS leads; EPO and PCT provide the main international pathways
The United States is the primary filing jurisdiction with 5,844 patent records, followed by the EPO at 4,062 and WIPO PCT at 3,465. Australia and Canada represent secondary validation markets. The relatively small count for the United Kingdom as a standalone jurisdiction likely reflects post-Brexit reclassification effects. Limited presence in Asian prosecution offices within this dataset may reflect scope rather than applicant behavior.
US-led, EPO/PCT followGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
Co-filing pairs, ranked by the number of jointly-filed patent families.
Genentech anchors the field; Janssen shows the strongest recent momentum among tracked leaders
The top-ranked applicants span large integrated biopharma, Roche-group entities, and specialist biotechs, with recent-period filing trajectories diverging meaningfully across the group.
Genentech Inc
Genentech holds 18,677 patent records, roughly double the nearest ranked challenger, reflecting multi-decade depth across antibody engineering, tumor antigen targeting, and combination therapy formats. Recent-period momentum shows a 15% decline versus the prior period, consistent with the field-wide plateau rather than a strategic retreat. Its portfolio breadth makes it the de facto prior-art reference point for any new entrant.
Records: 18,677Janssen Biotech Inc
Janssen Biotech ranks sixth overall with 4,022 patent records but stands out as the only top-tracked applicant showing a materially positive recent trajectory at +27% versus the prior period. This acceleration — while the broader field has eased from its 2021 peak — suggests active expansion into new bispecific formats or therapeutic indications. Janssen’s position within the Johnson & Johnson group provides regulatory and commercial infrastructure to advance pipeline assets rapidly.
Records: 4,022| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Genentech Inc | 152 | ▼ -15% |
| Regeneron Pharmaceuticals Inc | 279 | ▬ +3% |
| F. Hoffmann-La Roche Ltd | 134 | ▼ -32% |
| Janssen Biotech Inc | 204 | ▲ +27% |
| Hoffmann-La Roche Inc | 127 | ▼ -21% |
| Chugai Pharmaceutical Co Ltd | 49 | ▼ -44% |
| Merus NV | 70 | ▬ +4% |
Under-served branches in production biology and analytical methods
Relative to the dominant protein-chemistry and therapeutic-activity classes, several IPC branches show notably lower coverage within the bispecific antibody corpus, pointing to areas where the existing patent landscape is thinner.
C12N · Microorganisms & genetic engineering
C12N accounts for 4,474 records — substantial in absolute terms but representing only 8% of the total IPC-tagged activity, sparse relative to the dominant A61K and C07K classes. This branch covers the host-cell engineering, vector design, and gene-editing tools that underpin bispecific antibody manufacturing. Given that chain-pairing and expression-yield challenges remain active engineering problems, coverage here may be lagging the pace of underlying innovation. Teams with strength in synthetic biology or CHO-cell engineering could find room to establish positions.
Search this in Eureka →G01N · Material analysis & testing
G01N carries 2,117 records — roughly 4% of IPC-tagged activity — despite characterization and quality-control assays being integral to bispecific antibody development and regulatory submission. The sparsity may reflect that analytical method claims are often filed under therapeutic-application codes or kept as trade secrets. For organizations developing platform analytical workflows — including mass-spectrometry-based heterodimer confirmation or functional cell-based potency assays — this branch represents an area where patent coverage is comparatively thin and where a focused filing strategy could establish credibility.
Search this in Eureka →How leading applicants differ across technology routes
Strength of each leader across the main technology routes.
| Player | C07K 16 · Peptides & proteins | A61K 39 · Medicinal preparations | A61P 35 · Therapeutic activity of compounds | C12N 15 · Microorganisms & genetic engineering | A61K 47 · Medicinal preparations |
|---|---|---|---|---|---|
| Genentech Inc | Strong · 1,003 | Strong · 712 | Moderate · 413 | Moderate · 253 | Emerging · 177 |
| Regeneron Pharmaceuticals Inc | Strong · 971 | Moderate · 448 | Moderate · 372 | Emerging · 174 | Emerging · 101 |
| F. Hoffmann-La Roche Ltd | Strong · 868 | Strong · 508 | Moderate · 304 | Absent | Emerging · 63 |
| Janssen Biotech Inc | Strong · 483 | Strong · 311 | Strong · 306 | Absent | Absent |
| Chugai Pharmaceutical Co Ltd | Strong · 388 | Strong · 274 | Moderate · 120 | Moderate · 185 | Absent |
| Immunomedics Inc | Strong · 313 | Strong · 281 | Moderate · 120 | Moderate · 84 | Moderate · 147 |
Frequently asked questions
The corpus covers 13,688 patent families. The United States is the lead filing jurisdiction with 5,844 patent records, followed by the EPO at 4,062 and WIPO PCT at 3,465.
Genentech Inc holds the top position with 18,677 patent records, approximately double the second-ranked applicant, Regeneron Pharmaceuticals Inc, at 9,925 records.
Annual filing volume peaked in 2021 at 2,194 records and has eased since then. The field is assessed at a maturity stage. Figures for 2024 and 2025 are incomplete due to publication lag and should not be read as a sustained decline.
C07K (Peptides & proteins) and A61K (Medicinal preparations) dominate the IPC composition. C12N (Microorganisms & genetic engineering) and G01N (Material analysis & testing) are present but at lower relative levels, indicating comparative sparsity in production-biology and analytical-method filings.
Among the tracked top applicants, Janssen Biotech Inc shows the strongest upward trajectory at +27% in the recent period versus the prior period, while most other leading filers have seen flat or declining volumes consistent with the broader plateau.
C12N (Microorganisms & genetic engineering) at 8% of IPC-tagged records and G01N (Material analysis & testing) at 4% are the most notable under-served branches relative to the dominant therapeutic-application classes, particularly given their technical relevance to manufacturing and characterization workflows.
Ready to map your own bispecific antibody landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.